Expression Of Somatostatin Receptors (hSSTR2,5) MRNA In Digestive Tumours And The Clinical Value And Mechanism For Octreotide Treating Hepatocellular Carcinoma

Expression of mRNA for Somatostatin Receptors (SSTR2,5) in Digestive TumorsObjective: The digestive malignant tumors are the major part in all malignant tumors and they harm people's lives and health seriously.Our study was to detect the expression of mRNA for somatostatin receptor subtypes and to understand the differentiation of tumor tissue indirectly.Based on it we observed the effect of somatostatin in the treatment of digestive tumors. Materials and methods: 66 patients were included,44 men and 22 women ,the median age was 48.6 years. All the specimens were identified by surgery and the histopathology examination.Among these specimens there were 22 gastric carcinoma,22 colonic cancer,11 hepatocellular carcinoma,11 pancreatic cancer respectively.Gastric carcinoma,hepatocellular carcinoma and pancreatic cancer were classified according to the TNM classification of the International Union Against Cancer(UICC), colonic cancer was classified according to Dukes.The total RNA of tumor tissue samples were purified with Trizol and submitted to cRNA synthesis,after that,PCR amplification was carried out.The primers were designed base on the literatures and the cDNA sequence of SSTR2,5 and β-actin published by NCBI,and then ran agarose gels electrophoresis with the products of PCR amplification. The electrophoretic zones of DNA were examined and were taken pictures for analysis. Results: The difference of SSTR2 mRNA expression in tissue between hepatocellulau carcinoma and para-tumor was not obvious, while the obvious difference of expression frequency of SSTR2 mRNA was found(P<0.05);In gastric carcinoma,colonic cancer and pancrentic cancer,there's no obvious difference. The SSTR2 mRNA expression frequency is different in different tumors. compared with that of gastric carcinoma(36.4%),colonic cancer(31.8%) and pancreatic cancer(18.2%),there was majou difference(P<0.05).Different SSTR2 mRNA expression degree was found in different tumors,it's obviously higher in hepatocellular carcinoma compared with that of gastric carcinoma,colonic cancer and pancreatic cancer.The difference of SSTR5 mRNA expression frequency in digestive malignant tumors was not obvious,36,4% in gastric carcinoma,31.8% in colonic cancer,18.2% in hepatocellular carcinoma and 9.1% in pancreatic cancer,so does the difference of SSTR5 mRNA expression degree in digestive malignant tumors. Conclusion: 1,The expression of somatostatin receptor subtypes SSTR2,5 was observed in the tissue of gastric carcinoma,colonic cancer,hepatocellular cancinoma and pancreatic cancer, and most of them were SSTR2 subtype.　2,The expression frequency and expression degree of SSTR2 was different in different tumors, it's expression was higher in hepatocellular carcinoma than in gastric carcinoma,colonic cancer and pancrentic cancer.3,The expression frequency and expression degree of SSTR2,5 was correlated closely with the differentiation,lymphoglandula metastasis. It was correlated closely with tumor classification. 4,The determination of SSTR subtype was benefit for the treatment of gastric carcinoma,colonic cancer,hepatocellular carcinoma and pancreatic cancer.